Prevalence of symptomatic dry eye in breast cancer patients undergoing systemic adjuvant treatment: A cross-sectional study

Jinfei Ma, Emmanuel Eric Pazo, Zihao Zou, Feng Jin, Jinfei Ma, Emmanuel Eric Pazo, Zihao Zou, Feng Jin

Abstract

Objectives: To investigate the prevalence of symptomatic dry eye (SDE) on women undergoing systemic adjuvant therapy for breast cancer and its association with treatment settings.

Methods: Woman undergoing breast cancer systemic adjuvant therapy were included in exposure group. An age-matched non-treatment control group was recruited. This cross-sectional questionnaire-based study utilised validated Ocular Surface Disease Index (OSDI) and NCCN-FACT-Breast Cancer Symptom Index (NFBSI-16) questionnaires to determine the presence of SDE and investigate other breast cancer treatment complications. Additionally, demographic data and medical histories were collected.

Results: Of 423 eligible participants, 200 in each of the control group and the exposure group were included in the final analysis. The prevalence of SDE was 59.0% in breast cancer patients with adjuvant treatment, statistically significantly higher than 25.5% in the control group (P < 0.01). Additionally, exposure group experienced higher prevalence of moderate and severe SDE, which were 20.0% and 19.5% respectively compared with 9.0% and 4.0% in the control group (P = 0.002, P < 0.001). There was a significantly high prevalence of SDE among patients who had received over four cycles of systemic therapy (71.0%, P < 0.001) and the application of targeted therapy (71.2%, P = 0.014). The severity of SDE positively correlated with the cycles of treatment administered.

Conclusion: SDE was significantly predominant in women with breast cancer undergoing systemic adjuvant treatment. Our findings suggest dry eye assessments among patients receiving more than four cycles of chemotherapy or targeted therapy, thus early revealing possible dry eye conditions to both patients and clinicians for further specialized examination and treatment.

Keywords: Breast cancer; Chemotherapy; Dry eye; NFBSI-16; OSDI; PRO measures; Questionnaire; Targeted therapy.

Conflict of interest statement

Declaration of competing interest No conflicts of interest.

Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Figures

Fig. 1
Fig. 1
Study profile.
Fig. 2
Fig. 2
The Ocular Surface Disease Index (OSDI) questions and disease severity scale.
Fig. 3
Fig. 3
Ocular surface disease index scores severity analysis. Scatter plot representation of the total ocular surface disease index scores in control and exposure group. ∗∗∗∗Unpaired t-test with Welch’s correction, P < 0.0001.

References

    1. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. doi: 10.3322/caac.21492.
    1. Feng R.M., Zong Y.N., Cao S.M., Xu R.H. Current cancer situation in China: good or bad news from the 2018 global cancer statistics? Canc Commun. 2019;39:22. doi: 10.1186/s40880-019-0368-6.
    1. Li T., Mello-Thoms C., Brennan P.C. Descriptive epidemiology of breast cancer in China: incidence, mortality, survival and prevalence. Breast Canc Res Treat. 2016;159:395–406. doi: 10.1007/s10549-016-3947-0.
    1. DeSantis C.E., Ma J., Gaudet M.M., Newman L.A., Miller K.D., Goding Sauer A. Breast cancer statistics. CA Cancer J Clin. 2019;(69):438–451. doi: 10.3322/caac.21583. 2019.
    1. Sledge G.W. Curing metastatic breast cancer. J Oncol Pract. 2016;12:6–10. doi: 10.1200/jop.2015.008953.
    1. McDonald E.S., Clark A.S., Tchou J., Zhang P., Freedman G.M. Clinical diagnosis and management of breast cancer. J Nucl Med. 2016;57:9S–16S. doi: 10.2967/jnumed.115.157834.
    1. Henderson I.C., Berry D.A., Demetri G.D., Cirrincione C.T., Goldstein L.J., Martino S. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003;21:976–983. doi: 10.1200/JCO.2003.02.063.
    1. Cameron D., Piccart-Gebhart M.J., Gelber R.D., Procter M., Goldhirsch A., de Azambuja E. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet. 2017;389:1195–1205. doi: 10.1016/S0140-6736(16)32616-2.
    1. Von Minckwitz G., Procter M., De Azambuja E., Zardavas D., Benyunes M., Viale G. Adjuvant pertuzumab and trastuzumab in early her2-positive breast cancer. N Engl J Med. 2017;377:122–131. doi: 10.1056/NEJMoa1703643.
    1. Burstein H.J., Curigliano G., Loibl S., Dubsky P., Gnant M., Poortmans P. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann Oncol. 2019;30:1541–1557. doi: 10.1093/annonc/mdz235.
    1. National Comprehensive Cancer Network National comprehensive cancer network guidelines for breast cancer. 2020 BINV-M 1-2.
    1. Kunkler A.L., Binkley E.M., Mantopoulos D., Hendershot A.J., Ohr M.P., Kendra K.L. Known and novel ocular toxicities of biologics, targeted agents, and traditional chemotherapeutics. Graefe’s Arch Clin Exp Ophthalmol. 2019;257:1771–1781. doi: 10.1007/s00417-019-04337-8.
    1. Huillard O., Bakalian S., Levy C., Desjardins L., Lumbroso-Le Rouic L., Pop S. Ocular adverse events of molecularly targeted agents approved in solid tumours: a systematic review. Eur J Canc. 2014;50:638–648. doi: 10.1016/j.ejca.2013.10.016.
    1. McDonald M., Patel D.A., Keith M.S., Snedecor S.J. Economic and humanistic burden of dry eye disease in europe, north America, and asia: a systematic literature review. Ocul Surf. 2016;14:144–167. doi: 10.1016/j.jtos.2015.11.002.
    1. Stapleton F., Alves M., Bunya V.Y., Jalbert I., Lekhanont K., Malet F. TFOS DEWS II epidemiology report. Ocul Surf. 2017;15:334–365. doi: 10.1016/j.jtos.2017.05.003.
    1. Song P., Xia W., Wang M., Chang X., Wang J., Jin S. Variations of dry eye disease prevalence by age, sex and geographic characteristics in China: a systematic review and meta-analysis. J Glob Health. 2018;8 doi: 10.7189/jogh.08.020503.
    1. Craig J.P., Nichols K.K., Akpek E.K., Caffery B., Dua H.S., Joo C.K. TFOS DEWS II definition and classification report. Ocul Surf. 2017;15:276–283. doi: 10.1016/j.jtos.2017.05.008.
    1. Stern M.E., Beuerman R.W., Fox R.I., Gao J., Mircheff A.K., Pflugfelder S.C. The pathology of dry eye: the interaction between the ocular surface and lacrimal glands. Cornea. 1998;17:584–589.
    1. Fan Q., Pazo E.E., You Y., Zhang C., Zhang C., Xu L. Subjective quality of vision in evaporative dry eye patients after intense pulsed light. Photobiomodulation, Photomedicine, Laser Surg. 2020 doi: 10.1089/photob.2019.4788.
    1. Baudouin C. The pathology of dry eye. Surv Ophthalmol. 2001;45:S211–S220. doi: 10.1016/S0039-6257(00)00200-9.
    1. Takimoto B.C.H., Calvo E. Principles of oncologic pharmacotherapy. Cancer. 2008:23–42.
    1. Prensky C.J., Brissette A.R., Sippel K.C., Teitelbaum A. Springer International Publishing; 2018. Eye symptoms and toxicities of systemic chemotherapy. MASCC textb. Cancer support. Care surviv; pp. 563–583.
    1. Eisner A., Luoh S.W. Breast cancer medications and vision: effects of treatments for early-stage disease. Curr Eye Res. 2011;36:867–885. doi: 10.3109/02713683.2011.594202.
    1. Redmond N., While A. Dry eye syndrome (DES) and watering eyes. Br J Community Nurs. 2008;13:471–479. doi: 10.12968/bjcn.2008.13.10.31184.
    1. Hazin R., Abuzetun J.Y., Daoud Y.J., Abu-Khalaf M.M. Ocular complications of cancer therapy: a primer for the ophthalmologist treating cancer patients. Curr Opin Ophthalmol. 2009;20:308–317. doi: 10.1097/ICU.0b013e32832c9007.
    1. Jerkins G.W., Pattar G.R., Kannarr S.R. A review of topical cyclosporine a formulations— a disease-modifying agent for keratoconjunctivitis Sicca. Clin Ophthalmol. 2020;14:481–489. doi: 10.2147/OPTH.S228070.
    1. Jones L., Downie L.E., Korb D., Benitez-del-Castillo J.M., Dana R., Deng S.X. TFOS DEWS II management and therapy report. Ocul Surf. 2017;15:575–628. doi: 10.1016/j.jtos.2017.05.006.
    1. Dougherty B.E., Nichols J.J., Nichols K.K. Rasch analysis of the ocular surface disease index (OSDI) Investig Ophthalmol Vis Sci. 2011;52:8630–8635. doi: 10.1167/iovs.11-8027.
    1. Garcia S.F., Rosenbloom S.K., Beaumont J.L., Merkel D., Von Roenn J.H., Rao D. Priority symptoms in advanced breast cancer: development and initial validation of the national comprehensive cancer Network-Functional Assessment of Cancer Therapy-Breast Cancer Symptom Index (NFBSI-16) Value Health. 2012;15:183–190. doi: 10.1016/j.jval.2011.08.1739.
    1. Krohe M., Tang D.H., Klooster B., Revicki D., Galipeau N., Cella D. Content validity of the national comprehensive cancer network-functional assessment of cancer therapy-breast cancer symptom index (NFBSI-16) and patient-reported outcomes measurement information system (PROMIS) physical function short form with advanced breast cancer patients. 2019.
    1. Spelsberg H., Klueppel M., Reinhard T., Glaeser M., Niederacher D., Beckmann M.W. Detection of Oestrogen receptors (ER) α and β in conjunctiva, lacrimal gland, and tarsal plates. Eye. 2004;18:729–733. doi: 10.1038/sj.eye.6701314.
    1. Ogueta S.B., Schwartz S.D., Yamashita C.K., Farber D.B. Estrogen receptor in the human eye: influence of gender and age on gene expression. Investig Ophthalmol Vis Sci. 1999;40:1906–1911.
    1. Gorin M.B., Day R., Costantino J.P., Fisher B., Redmond C.K., Wickerham L. Long-term tamoxifen citrate use and potential ocular toxicity. Am J Ophthalmol. 1998;125:493–501. doi: 10.1016/s0002-9394(99)80190-1.
    1. Eisner A., Toomey M.D., Falardeau J., Samples J.R., Vetto J.T. Differential effects of tamoxifen and anastrozole on optic cup size in breast cancer survivors. Breast Canc Res Treat. 2007;106:161–170. doi: 10.1007/s10549-006-9486-3.
    1. Inglis H., Boyle F.M., Friedlander M.L., Watson S.L. Dry eyes and AIs: if you don’t ask you won’t find out. Breast. 2015;24:694–698. doi: 10.1016/j.breast.2015.08.008.
    1. Kalra R., Chavada B., Madhani N.R., Purohit B., Tripathi C.B. Cyclophosphamide and/or anthracyclines induced epiphora in breast cancer patients: a rare side-effect. Curr Drug Saf. 2018;13:62–64. doi: 10.2174/1574886312666170919175614.
    1. Rowinsky M.D.E.K. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med. 1997;48:353–374. doi: 10.1146/annurev.med.48.1.353.
    1. Esmaeli B., Amin S., Valero V., Adinin R., Arbuckle R., Banay R. Prospective study of incidence and severity of epiphora and canalicular stenosis in patients with metastatic breast cancer receiving docetaxel. J Clin Oncol. 2006;24:3619–3622. doi: 10.1200/JCO.2005.04.4453.
    1. Esmaeli B., Ahmadi M.A., Rivera E., Valero V., Hutto T., Jackson D.M. Docetaxel secretion in tears: association with lacrimal drainage obstruction. Arch Ophthalmol. 2002;120:1180–1182. doi: 10.1001/archopht.120.9.1180.
    1. Verrill M. Chemotherapy for early-stage breast cancer: a brief history. Br J Canc. 2009;101:S2–S5. doi: 10.1038/sj.bjc.6605268.
    1. Eiseman A.S., Flanagan J.C., Brooks A.B., Mitchell E.P., Pemberton C.H. Ocular surface, ocular adnexal, and lacrimal complications associated with the use of systemic 5-Fluorouracil. Ophthalmic Plast Reconstr Surg. 2003;19:216–224. doi: 10.1097/01.IOP.0000066648.33513.3D.
    1. Schmid K.E., Kornek G.V., Scheithauer W., Binder S. Update on ocular complications of systemic cancer chemotherapy. Surv Ophthalmol. 2006;51:19–40. doi: 10.1016/j.survophthal.2005.11.001.
    1. Chan A., Su C., de Boer R.H., Gajdatsy A. Prevalence of excessive tearing in women with early breast cancer receiving adjuvant docetaxel-based chemotherapy. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31:2123–2127. doi: 10.1200/JCO.2012.45.6574.
    1. Untch M., Rezai M., Loibl S., Fasching P.A., Huober J., Tesch H. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28:2024–2031. doi: 10.1200/JCO.2009.23.8451.
    1. Peck T., Olsakovsky L., Aggarwal S. Dry eye syndrome in menopause and perimenopausal age group. J Midlife Health. 2017;8:51–54. doi: 10.4103/jmh.JMH_41_17.
    1. Bouchardy C., Usei M., Verkooijen H.M., Fioretta G., Benhamou S., Neyroud-Caspar I. Changing pattern of age-specific breast cancer incidence in the Swiss canton of Geneva. Breast Canc Res Treat. 2010;120:519–523. doi: 10.1007/s10549-009-0478-y.
    1. Sriprasert I., Warren D.W., Mircheff A.K., Stanczyk F.Z. Dry eye in postmenopausal women. Menopause. 2016;23:343–351. doi: 10.1097/GME.0000000000000530.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다